NCT07722754
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
Recruiting · Phase 2 · Guangdong Provincial People's Hospital · registry updated 2026-09-24
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Primary endpoint: objective response rate Secondary endpoints: progression-free survival (PFS), overall survival (OS) and adverse events.
Inclusion
- Metastatic and unresectable colorectal adenocarcinom;
- RAS wild-type and MSS tumor;
- Measurable lesions;
- Failed to at least two lines of standard treatment containing fluoropyrimidine, irinotecan and bevacizumab;
- Eastern Cooperative Oncology Group performance status 2 or less;
- White blood cell≥ 3\*10\^9/L, neutrophil≥ 1.5\*10\^9/Lplatelet count≥75\*10\^9/L, hemoglobin≥60g/L;
Exclusion
- Other aggressive malignancies within 3 years (Exceptions: non-melanoma skin cancer or carcinoma-in-situ of the cervix that has been treated);
- Allergy or intolerance to any of the study drugs;
- Human immunodeficiency virus positive;
- Concurrent anti-cancer therapy including radiation therapy, chemotherapy, targeted agents or biological agents not otherwise specified within two weeks;
- Malignant bowel obstruction;
- Prior treatment with PD-1 antibody;